CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.51 · Revenue $29.17M · 4 analysts
Est. EPS $-0.44 · Revenue $31.73M · 4 analysts
Est. EPS $-1.97 · Revenue $115.54M · 6 analysts
Est. EPS $-0.41 · Revenue $34.10M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $89.1M | +36.1% | +6.1% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-53.4M | -32.0% | +2.4% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +87.9% | +1.4% | +5.8% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -65.6% | -8.1% | +9.2% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -60.0% | +3.0% | +7.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-41.6M | -14.3% | +31.5% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -46.7% | +16.0% | +35.4% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 14.3% | +24.8% | +8.7% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 9.73x | -41.8% | -10.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $195.8M | -13.1% | -6.6% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.46 vs -1.51 | +3.1% | -0.51 vs -0.51 | -0.1% |
| Revenue Surprise | $89.1M vs $88.2M | +1.0% | $28.1M vs $29.2M | -3.7% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 24, 2026 | Foehr David | officer: Senior VP, Finance and PAO | Common Stock | D | 859 | $23.95 |
| Aug 21, 2026 | Manni Joseph S. | officer: Chief Revenue Officer | Common Stock | D | 1,361 | $24.02 |
| Aug 21, 2026 | Foehr David | officer: Senior VP, Finance and PAO | Common Stock | D | 993 | $24.02 |
| Aug 21, 2026 | Woo Raymond | officer: Chief Technology Officer | Common Stock | D | 1,979 | $24.02 |
| Aug 21, 2026 | Blumberg Scott | officer: Chief Financial Officer | Common Stock | D | 1,521 | $24.02 |
Operator: Ladies and gentlemen, thank you for standing by. My name is Dejirae and I will be your conference operator today. At this time, I would like to welcome everyone to Ceribell Q2 26 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, I would now like to turn the call over to Brian Johnston of Gilmartin Group. You may begin. Brian Johnston: Good afternoon, and thank you all for participating in today's call. Joining me from Ceribell are Jane Chao, Co Founder and Chief Executive Officer and Scott Blumberg, Chief Financial Officer. Earlier today, Ceribell issued a press release announcing financial results for the quarter ended June 2026. A copy of the press release is available on the Investor Relations section of the company's website. Before we begin, I would like to remind you that management will make remarks during this call that include forward looking statements within the meaning of federal securities laws and that these are being made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 2 thousand. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward looking statements. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied. By these forward looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our public filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed with the SEC on 02/24/2026, and quarterly report on Form 10 Q for the quarter ended 06/30/2026. This conference call contains time sensitive information and is accurate only as of the live broadcast today, 08/10/2026. Ceribell disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements because of new information, future events or otherwise. And with that, I will turn the call over to Jane. Xingjuan Chao: Good afternoon, and thank you for joining us for our second quarter 2026 earnings call. Q2 launched another strong quarter for Ceribell. As we delivered revenue of $28.1 million growing 33% year over year. This is an acceleration from the 29% year over year growth we reported in Q1 which reflects a particularly strong performance in same store growth driven by our clinical account management team. We also increased our account base by 32 accounts. To a total of 712 active accounts. While the increase is …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Xingjuan Chao | Co-Founder, President, Chief Executive Officer & Director | USD 1,284,510 | Female | 1981 | Active |
Scott Blumberg | Chief Financial Officer | USD 677,065 | Male | — | Active |
Raymond Woo | Chief Technology Officer | USD 657,085 | Male | 1983 | Active |
Josef Parvizi | Co-Founder, Chief Medical Advisor & Director | USD 242,525 | — | 1969 | Active |
Brian Price | Senior Vice President of Marketing | — | Male | — | Active |
Dan Rogy | Senior Vice President of Operations | — | Male | — | Active |
Joseph S. Manni | Chief Revenue Officer | — | Male | 1974 | Active |
Baharan Kamousi | Senior Vice President of Data Science | — | Female | — | Active |
Kim McKeon | Vice President of People & Culture | — | Female | — | Active |
Louisa Daniels | General Counsel | — | Female | 1958 | Active |
CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.
CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring solution later this year.
